Shandong Sito Bio-technology Bundle
Who Really Owns Shandong Sito Bio-technology?
Unraveling the ownership structure of a company is like peering into its very soul, revealing the forces that shape its destiny. For Shandong Sito Bio-technology, a key player in the life sciences sector, understanding its ownership is paramount. From its roots in Shandong, China, to its current status as a publicly traded entity, the evolution of Sito Bio-technology ownership tells a compelling story.
This exploration of Shandong Sito Bio-technology SWOT Analysis will illuminate the key players behind this biotechnology company, from the initial founders to the current shareholders. We will investigate the impact of its 2017 IPO and the subsequent shifts in ownership, providing a clear picture of who controls the strategic direction of Shandong Sito Bio-technology. Understanding the ownership of a company is crucial for investors, and this article aims to provide a comprehensive overview of Sito Bio-technology ownership.
Who Founded Shandong Sito Bio-technology?
The founding of Shandong Sito Bio-technology Co., Ltd., a key player in the biotechnology sector, is a significant aspect of understanding its current ownership structure. While the exact founding year is debated, with sources citing both 2002 and 2010, the company's origins are rooted in the development and production of steroid drug raw materials and related intermediates.
The leadership of Qi Mi, who serves as the legal representative, general manager, and Chairman of the Board, highlights his pivotal role since the company's inception. This concentration of leadership positions suggests a strong influence from the founding stage, shaping the company's strategic direction and operational focus.
Details regarding the initial equity distribution among the founders remain undisclosed in public records. However, the successful listing on the Shenzhen Stock Exchange in 2017 marked a crucial step in the company's growth trajectory, allowing it to attract further investment and expand its operations.
Key Leadership
Qi Mi is the legal representative, general manager, and Chairman of the Board. This multiple leadership role indicates his significant influence from the company's founding.
Founding Year Discrepancy
The exact founding year is uncertain; some sources state 2002, while others indicate 2010. This highlights the importance of verifying historical data.
Focus on R&D
The company's focus on developing and producing steroid drug raw materials and intermediates reflects a commitment to R&D and innovation.
Public Listing
Listing on the Shenzhen Stock Exchange in 2017 was a key milestone. This event facilitated access to capital and enhanced the company's profile.
Early Investors
Specific details about early backers or angel investors are not available in public records. The company's growth trajectory has been notable.
Technology Focus
The company utilizes genetic engineering and microbial transformation technologies. This focus underscores its commitment to advanced biopharmaceutical processes.
Ownership Insights
Understanding the origins of Shandong Sito Bio-technology is crucial for analyzing its current company ownership. The key figure, Qi Mi, has a significant influence, holding multiple leadership roles. The company's evolution from its founding, whether in 2002 or 2010, to its public listing in 2017 showcases its growth. For more details, you can read a Brief History of Shandong Sito Bio-technology.
- Who owns Sito Bio-technology is a question that can be partially answered by examining the roles of its key leaders.
- The company's focus on biotechnology, particularly in steroid drug raw materials, highlights its specialized market position.
- The successful listing on the Shenzhen Stock Exchange has provided access to capital, driving further expansion and development.
- The company's location in Shandong China is a key factor in its operational and strategic context.
Shandong Sito Bio-technology SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Shandong Sito Bio-technology’s Ownership Changed Over Time?
The evolution of Shandong Sito Bio-technology's ownership structure began with its initial public offering (IPO) on the Shenzhen Stock Exchange on January 6, 2017. The IPO saw 26.67 million shares offered at an issue price of 40.29 CNY per share. This event marked the transition of Shandong Sito Bio-technology from a privately held entity to a publicly traded company, opening it up to a wider range of investors and fundamentally changing its ownership dynamics.
As of June 12, 2025, the company's stock price was $2.56. The company has a market capitalization of $485 million with 190 million shares outstanding. This shift in status has made it a subject of interest for various institutional and individual investors, influencing its strategic direction and governance.
| Date | Event | Impact on Ownership |
|---|---|---|
| January 6, 2017 | IPO on Shenzhen Stock Exchange | Transitioned from private to public ownership, introducing institutional and individual investors. |
| June 4, 2025 | Institutional Ownership Data | Institutional ownership was 0.35%, and insider ownership was 0.00%. |
| December 31, 2024 | Shareholder Disclosures | ChinaAMC Panrui 1-Y Interval Alloc A held 0.21% of total shares, and TAIPING JiaHe 3M Interval Bd held 0.05%. |
The ownership of Shandong Sito Bio-technology is a mix of institutional and individual investors. As of June 4, 2025, institutional ownership stood at 0.35%, while insider ownership was 0.00%. Major institutional shareholders include China Asset Management Co., Ltd., Taiping Fund Management Co., Ltd., and others. These institutional investors often play a significant role in shaping the company's strategy. For a deeper dive into the company's strategic approach, you can also explore the Growth Strategy of Shandong Sito Bio-technology.
Key Takeaways on Sito Bio-technology Ownership
Shandong Sito Bio-technology became a public company in 2017, which changed its ownership structure.
- Institutional investors hold a portion of the company's shares.
- The stock price and market capitalization reflect investor confidence and market conditions.
- Understanding the shareholder base is crucial for assessing the company's future direction.
- The company is based in Shandong, China.
Shandong Sito Bio-technology PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Shandong Sito Bio-technology’s Board?
The current leadership of Shandong Sito Bio-technology includes Qi Mi as Chairman and General Manager. Xu Sheng Kong, Lu Li, and Ya Ping Ma also serve as directors. Lu Li holds additional roles as Deputy General Manager and Board Secretary. The independent directors are Li Kang, Qi Ming Zhang, and Peng Fei Tu. Chao Chao Liu and Yingying Zhang are supervisors, with Wen Xia Zhang as the Chairman of the Supervisory Board.
Understanding the Sito Bio-technology ownership structure is crucial for investors. The company's board includes a mix of executive and independent directors. This structure is typical for companies in Shandong, China, and aims to balance management and shareholder interests. Further details on Sito Bio-technology ownership, including major shareholders, can often be found in the company's annual reports or filings with regulatory bodies.
| Role | Name | Title |
|---|---|---|
| Chairman & General Manager | Qi Mi | Director |
| Director | Xu Sheng Kong | Director |
| Director, Deputy General Manager, Board Secretary | Lu Li | Director |
| Director | Ya Ping Ma | Director |
| Independent Director | Li Kang | Independent Director |
| Independent Director | Qi Ming Zhang | Independent Director |
| Independent Director | Peng Fei Tu | Independent Director |
| Supervisor | Chao Chao Liu | Supervisor |
| Supervisor | Yingying Zhang | Supervisor |
| Chairman of the Supervisory Board | Wen Xia Zhang | Chairman |
While specific voting structures aren't always publicly available, the presence of independent directors and a supervisory board suggests a focus on corporate governance. For detailed information on the Company ownership and voting rights, investors should consult the official company documentation. Analyzing the board composition provides insights into the strategic direction of the Biotechnology company.
Key Takeaways on Board and Governance
The board includes both executive and independent directors, indicating a balanced approach to governance.
- Qi Mi serves as Chairman and General Manager.
- Independent directors include Li Kang, Qi Ming Zhang, and Peng Fei Tu.
- The Supervisory Board is chaired by Wen Xia Zhang.
- This structure is common for Shandong China-based companies.
Shandong Sito Bio-technology Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Shandong Sito Bio-technology’s Ownership Landscape?
In the past few years, Shandong Sito Bio-technology has shown several financial and operational shifts. As of March 31, 2025, the company's trailing 12-month revenue was reported at $137 million. Financial performance has been mixed, with a decrease in net income. For instance, in the first three quarters of 2024, net income dropped by 75.94% to 14.7153 million yuan. The first half of 2024 saw a net income of 13.2114 million yuan, a year-on-year decrease of 77.97%. The basic earnings per share for the first half of 2024 were 0.07 yuan.
Shandong Sito Bio-technology also approved a profit distribution plan for 2024, with a cash dividend of CNY 0.10000000 per ten shares. For the year 2023, a final cash dividend of CNY 4.50000000 per ten A shares was announced, payable on July 30, 2024. These financial results reflect a period of adjustment and challenges for the biotechnology company.
| Metric | Value | Date |
|---|---|---|
| Trailing 12-Month Revenue | $137 million | March 31, 2025 |
| Institutional Ownership | 0.35% | June 4, 2025 |
| Net Income (Q1-Q3 2024) | 14.7153 million yuan (decrease of 75.94%) | 2024 |
| Net Income (H1 2024) | 13.2114 million yuan (decrease of 77.97%) | 2024 |
Regarding Sito Bio-technology ownership, institutional ownership decreased to 0.35% as of June 4, 2025, down from 0.41% at the end of January 2025 and 2.29% in the latter half of 2024. Insider ownership remained steady at 0.00% during the same period. The company has stated on May 30, 2025, that there are no current plans for restructuring or significant mergers and acquisitions. This suggests a stable core ownership structure, with a slight reduction in institutional investment. If you are interested in the Shandong China market, you might find this article helpful: Target Market of Shandong Sito Bio-technology.
Who Owns Sito Bio-technology?
The ownership structure of Shandong Sito Bio-technology includes institutional investors and insiders. Institutional ownership has seen a decrease, while insider ownership has remained constant. Understanding the ownership trends provides insights into the biotechnology company's stability.
Financial Performance
The company's financial performance has shown fluctuations. Revenue for the trailing 12 months was $137 million. Net income decreased in 2024, with earnings per share at 0.07 yuan for the first half of the year.
Dividend Information
Shandong Sito Bio-technology approved a dividend plan for 2024, with a cash dividend of CNY 0.10000000 per ten shares. A final cash dividend of CNY 4.50000000 per ten A shares was paid on July 30, 2024, for the year 2023.
Future Plans
The company has stated no current plans for restructuring or significant mergers and acquisitions. This indicates a focus on maintaining the current operational structure. These trends provide key insights into Shandong Sito Bio-technology.
Shandong Sito Bio-technology Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Shandong Sito Bio-technology Company?
- What is Competitive Landscape of Shandong Sito Bio-technology Company?
- What is Growth Strategy and Future Prospects of Shandong Sito Bio-technology Company?
- How Does Shandong Sito Bio-technology Company Work?
- What is Sales and Marketing Strategy of Shandong Sito Bio-technology Company?
- What is Brief History of Shandong Sito Bio-technology Company?
- What is Customer Demographics and Target Market of Shandong Sito Bio-technology Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.